Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
Phase 1 Completed
26 enrolled 24 charts
Romidepsin Maintenance After Allogeneic Stem Cell Transplantation
Phase 1 Completed
23 enrolled
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Phase 1 Terminated
17 enrolled
A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma
Phase 1 Completed
16 enrolled
Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas
Phase 1 Completed
5 enrolled
FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma
Phase 2 Terminated
4 enrolled 4 charts
PDX+Romi
Phase 1/2 Completed
57 enrolled
Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas
Phase 1 Completed
24 enrolled
Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma
Phase 1 Completed
24 enrolled
A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)
Phase 2 Completed
102 enrolled 15 charts
Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma
Phase 1 Terminated
7 enrolled 11 charts
Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma
Phase 1 Terminated
3 enrolled
Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
Phase 2 Completed
131 enrolled 18 charts
Long-term Use of Romidepsin in Patients With CTCL
Completed
47 enrolled
Depsipeptide in Treating Patients With Solid Tumors
Phase 1 Completed